PMID- 34190171
OWN - NLM
STAT- MEDLINE
DCOM- 20210708
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 26
DP  - 2021 Jul 2
TI  - Immunoadsorption treatment for dilated cardiomyopathy: A PRISMA-compliant 
      systematic review and meta-analysis.
PG  - e26475
LID - 10.1097/MD.0000000000026475 [doi]
LID - e26475
AB  - BACKGROUND: As one of the leading causes of heart failure, dilated cardiomyopathy 
      (DCM) is characterized by dysfunctional muscle contraction and enlarged 
      ventricular chamber. Patients with DCM have been shown to respond well to 
      immunoadsorption (IA) therapies. However, the efficacy and safety of IA treatment 
      for DCM patients remained to be evaluated. METHODS: This study was designed in 
      accordance with the Preferred Reporting Items for Systematic Review and 
      Meta-analysis. We searched the databases such as Cochrane library, Cochrane 
      Central Register of Controlled Trials, Embase, OVID, and Web of Science from 
      January 1990 to March 20, 2020, and performed meta-analysis using Stata MP 
      Version 13.0. RESULTS: We performed meta-analysis on 12 studies that included a 
      total of 395 patients with DCM. Overall, IA treatment significantly improved the 
      left ventricular ejection fraction (6.01, 95% confidence interval [CI] 
      [4.84-7.19]), reduced the left ventricular end diastolic diameter (-3.62, 95% CI 
      [-4.06 to -3.19]), reduced severity of symptoms according to the New York Heart 
      Association (NYHA) functional classification (-1.37, 95% CI [-1.73 to -1.02]) as 
      compared with the controls, but had no effect on values for safety parameters 
      (1.13, 95% CI [0.58-2.19]). CONCLUSIONS: Results of this meta-analysis indicated 
      that the IA treatment can improve the left ventricular ejection fraction, reduce 
      left ventricular end diastolic diameter, and thus improve clinical outcome in DCM 
      patients. However, further evidence are required to validate the relative safety 
      of IA treatment. Multi-center, double blind studies should be conducted to 
      elucidate the precise effect of IA treatment in DCM patients.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Bian, Ru-Tao
AU  - Bian RT
AUID- ORCID: 0000-0001-7877-010
AD  - Department of Cardiology, Henan University of Chinese Medicine.
FAU - Wang, Zhen-Tao
AU  - Wang ZT
AD  - Department of Cardiology, The Second Affiliated Hospital of Henan University of 
      Chinese Medicine.
FAU - Li, Wei-Yu
AU  - Li WY
AD  - Department of Nephropathy, Zhengzhou Traditional Chinese Medicine Hospital, 
      Zhengzhou, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
SB  - IM
MH  - Cardiomyopathy, Dilated/*therapy
MH  - Humans
MH  - Plasmapheresis/*methods
MH  - Treatment Outcome
PMC - PMC8257917
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2021/07/01 06:00
MHDA- 2021/07/09 06:00
PMCR- 2021/07/02
CRDT- 2021/06/30 09:09
PHST- 2020/11/11 00:00 [received]
PHST- 2021/06/07 00:00 [accepted]
PHST- 2021/06/30 09:09 [entrez]
PHST- 2021/07/01 06:00 [pubmed]
PHST- 2021/07/09 06:00 [medline]
PHST- 2021/07/02 00:00 [pmc-release]
AID - 00005792-202107020-00030 [pii]
AID - MD-D-20-11038 [pii]
AID - 10.1097/MD.0000000000026475 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Jul 2;100(26):e26475. doi: 
      10.1097/MD.0000000000026475.